Zoran Ivanovic, Etablissement Français du Sang Aquitaine-Limousin, Place Amélie Raba Léon, BP24, 33035 Bordeaux Cedex, France.
World J Stem Cells. 2010 Apr 26;2(2):18-23. doi: 10.4252/wjsc.v2.i2.18.
In this paper, experimental findings concerning the kinetics of hematopoietic reconstitution are compared to corresponding clinical data. Although not clearly apparent, the transplantation practice seems to confirm the basic proposals of experimental hematology concerning hematopoietic reconstitution resulting from successive waves of repopulation stemming from different subpopulations of progenitor and stem cells. One of the "first rate" parameters in clinical transplantations in hematology; i.e. the CD34+ positive cell dose, has been discussed with respect to the functional heterogeneity and variability of cell populations endowed by expression of CD34. This parameter is useful only if the relative proportion of stem and progenitor cells in the CD34+ cell population is more or less maintained in a series of patients or donors. This proportion could vary with respect to the source, pathology, treatment, processing procedure, the graft ex vivo treatment and so on. Therefore, a universal dose of CD34+ cells cannot be defined. In addition, to avoid further confusion, the CD34+ cells should not be named "stem cells" or "progenitor cells" since these denominations only concern functionally characterized cell entities.
本文将造血重建的动力学实验结果与相应的临床数据进行了比较。虽然不是很明显，但移植实践似乎证实了实验血液学的基本假设，即造血重建是由不同祖细胞和干细胞亚群产生的连续再群体引发的。在血液学的临床移植中，有一个“首要”参数，即 CD34+阳性细胞剂量，已经根据表达 CD34 的细胞群体的功能异质性和可变性进行了讨论。只有在一系列患者或供者中，CD34+细胞群体中的干细胞和祖细胞的相对比例或多或少保持不变的情况下，这个参数才有用。这种比例可能会因来源、病理学、治疗、处理程序、体外处理移植物等而有所不同。因此，不能定义通用剂量的 CD34+细胞。此外，为了避免进一步混淆，CD34+细胞不应该被命名为“干细胞”或“祖细胞”，因为这些名称仅涉及功能上已确定的细胞实体。
